Fig. 1 · Structure

Documents & Downloads

R547

Cat. No. A11190 CAS 741713-40-6

CDK inhibitor

R547 is a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs) (Ki = 1, 3, and 1 nM for CDK1, CDK2, and CDK4, respectively) with excellent in vitro cellular potency that inhibits the growth of various human tumor cell lines.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
CDK4/CyclinD1 ki 1nM
CDK1/CyclinB ki 2nM
CDK2/CyclinE ki 3nM
PKA ki >5μM
PKB ki >5μM
PKCα ki >5μM
PKCβ ki >5μM
Fyn ki >5μM
EphB3 ki >5μM
SGK ki >5μM
KDR ki >5μM
FGFR ki >5μM
EGFR ki >5μM
PDGFR ki >5μM
IGFR ki >5μM
Src ki >5μM
FAK ki >5μM
AuroraA ki >5μM
GSK-3β ki 8μM
p38 ki >50μM
MAPK2 ki >50μM

21 targets · Scroll to view more

R547 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of R547 from 3 published references. In vitro models include PANC1 cells; human HCC cell line Hep G2.

R547 In Vitro Studies

R547 at 0.02 μM for 72 h did not induce CEBPD mRNA levels in PANC1 cells. In human HCC Hep G2 cells, the IC50 inhibition concentration of R547 was 88 μM for 48 h. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

CEBPD mRNA Expression in PANC1 Cells

Cell-based study · PANC1 cells [1]

PANC1 cells were treated with the compound at 0.02 μM for 72 h, with DMSO as the negative control. Treatment did not induce CEBPD mRNA levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CEBPD mRNA expressionReported result did not induce CEBPD mRNA levels in PANC1 cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.02 μM
Exposure duration
t = 72 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: R547

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Validation of C/EBPδ‐Activating Compounds in PDAC Cells (S70, S71, S76); FIGURE 5 legend (S95, S96, S99)

CEBPD mRNA expression: CEBPD mRNA expression; comparator: DMSO (solvent) was used as negative, no treatment, control — Results > Validation of C/EBPδ‐Activating Compounds in PDAC Cells (S76); FIGURE 5 legend (S95)

Cell survival in hepatocellular carcinoma cells

Cell-based study · human HCC cell line Hep G2 [2]

Human HCC Hep G2 cells were treated with R547 and assessed for cell survival. The reported IC50 was 88 μM after 48 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
survival rates of the cellsIC50 88 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.1, 1, 10, 50, and 100 µM
Exposure duration
48 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: R547

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and methods > 2.1. Cell culture and groups (S1, S3, S4, S6); 2. Materials and methods > 2.2. Cell survival analysis (S9, S10); 3. Results > 3.1. Analyzing cell survival by MTT assay (S45)

survival rates of the cells: survival rates of the cells; comparator: only feeding medium — 2. Materials and methods > 2.2. Cell survival analysis (S9); 3. Results > 3.1. Analyzing cell survival by MTT assay (S45)

R547 In Vivo Studies

In the αCre;Rb f/f;p27−/− mouse model, pregnant dams received daily I.P. injections of R547 at 20 mg/kg from embryonic day 12.5 to parturition. Of 8 eyes examined in the treatment group, 6 eyes were tumor-free. [3]

Tumor frequency in a mouse model

Animal study · αCre;Rb f/f;p27−/− mice [3]

Pregnant dams received daily I.P. injections of vehicle or R547 (20 mg/kg) from embryonic day 12.5 (E12.5) to parturition and tumors were assessed at P45. Of 8 eyes examined in the treatment group, 6 eyes were tumor-free.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor frequencyReported result Of 8 eyes examined in the treatment group, 6 eyes were tumor-free[3]

Conditions shared by the study groups

Route
I.P. injections
Treatment course
pregnant dams received daily I.P. injections of vehicle or R547 (20 mg/kg) from embryonic day 12.5 (E12.5) to parturition and tumors were assessed at P45.
Vehicle
2.5% v/v DMSO (5% for 20 mg/kg dose), 28% w/v 2-hydroxypropyl-β-cyclodextrin, 10% v/v PEG400 in distilled water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
R547 20 mg/kgvehicle (n=8)Of 8 eyes examined in the treatment group, 6 eyes were tumor-free[3]
R547 20 mg/kg
Model: αCre;Rb f/f;p27−/− mice
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: R547

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Inhibiting Either of the Dual Axes Blocks Tumorigenesis (S61, S62); MATERIALS AND METHODS > Chemoprevention (S103); Figure 6 legend (S149)

tumor frequency: tumor frequency; comparator: vehicle (n=8) — RESULTS > Inhibiting Either of the Dual Axes Blocks Tumorigenesis (S62)

R547 20 mg/kg · RESULTS > Inhibiting Either of the Dual Axes Blocks Tumorigenesis (S61, S62)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 741713-40-6
Applications CDK inhibitor
Formula C18H21F2N5O4S
Molecular Weight 441.45
SMILES
COC1=C(C(=C(C=C1)F)F)C(=O)C2=CN=C(N=C2N)NC3CCN(CC3)S(=O)(=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 56 mg/mL (126.85 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% hydroxyethyl cellulose+0.2% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

R547 Research References

  1. [1] Hartl L, Duitman J, Aberson HL, et al. Identification of C/EBPδ-Modifying Compounds as Potential Anticancer Agents Using a High-Throughput Drug Screen. J Cell Mol Med (2025). PMID: 39887610 DOI: 10.1111/jcmm.70287 Source material
  2. [2] Hacioğlu B, Kuş G, Kutlu HM, et al. The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death. Turk J Biol (2020). PMID: 32123493 DOI: 10.3906/biy-1907-3 Source material
  3. [3] Sangwan M, McCurdy SR, Livne-Bar I, et al. Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation. Oncogene (2012). PMID: 22286767 DOI: 10.1038/onc.2011.654 Source material

Added to your cart

View Cart Checkout
Loading...